b'LORETTA SHAW-LORELLO Member, Corporate, New YorkLoretta advises private equity fund sponsors on a broad range of issues with respect to fund formation, operation, and regulatory compliance. She has extensive experience representing clients in the formation and operation of buyout funds, venture capital funds, real estate funds, distressed funds, and credit opportunity funds. She also counsels fund sponsors on the formation and operation of investment manager and general partner entities, including FULL BIO ON MINTZ.COMinvestment adviser registration and compliance and structuring carried interest plans and employee co-investment arrangements. KAITLYN SPRAGUE Director of Government Relations, ML Strategies, BostonKaitlyn has over a decade of experience in legislative affairs and Massachusetts state government and brings a deep understanding of Massachusetts legislative proceedings, especially matters regarding the Massachusetts House of Representatives and the Governors Office. As the Legislative Director in Governor Bakers Office of Legislative Affairs, she drove the Governors legislative agenda from filing to passage, through bipartisan coalition building, legislative FULL BIO ON MLSTRATEGIES.COMstrategy sessions, and consistent communication with the legislature. Earlier Kaitlyn served as the Legislative Director to Minority Leader Bradley H. Jones Jr.KAREN WON Member, Intellectual Property, New YorkKaren has comprehensive experience across all aspects of a trademark practice: counseling, disputes, prosecution, and transactions. She also handles matters relating to copyright and false advertising. Her clients include many companies in the life sciences sectors, particularly in pharmaceuticals, biotechnology, and medical devices, as well as companies in the broader technology sector, including e-commerce, mobile apps, and SaaS. She has particular experience FULL BIO ON MINTZ.COMin counseling life sciences clients on branding matters, including the selection, clearance, strategy, and commercialization of drug brands, including advising on the complex overlay of drug name requirements at the USPTO and FDA to obtain requisite approvals.9'